NDRC To Transfer Pharmaceutical Administration Responsibility To MIIT
This article was originally published in PharmAsia News
China's National Development and Reform Commission recently announced that it has received the State Council's approval for its proposed bill of determining function, organization structure and staff allocation. In future, NDRC will reduce the responsibilities of its involvement in micro-administration and assessment of specific projects. Meanwhile, Ministry of Industry and Information Technology of the People's Republic China will undertake NDRC's current portfolio of industry and information management. This includes biopharmaceutical programs, regulations and standards, organizational implementation, as well as national medical reserves. (Click here for more - Chinese Language)
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.